Inflammatory Skin Disease Summit 2014

Transcription

November 19 – 21, 2014
Inflammatory Skin Disease
Summit 2014
The Translational Revolution
Austrian Academy of Sciences
Dr. Ignaz Seipel-Platz 2, Vienna, Austria
FINAL PROGRAMME
ORGANISED BY: Austrian Academy of Sciences
www.oeaw.ac.at/isds2014
II
Neu
bei Psoriasis-Arthritis
Prix Galien USA for Best Biotechnology Product
Symptomkontrolle
bis in die Fingerspitzen 2
nach zwei Initialdosen
subkutan alle 12 Wochen1
starke, anhaltende Wirkung
in der Psoriasis-Arthritis2
hemmt gezielt die
inflammatorischen Zytokine
Interleukin-12 und -23 1
1. Fachinformation Stelara®, 20.03.20147
2. McInnes I. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis:
1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
Lancet 2013 Jun 12. doi: 10.1016/S0140-6736(13) 60594-2
FACHKURZINFORMATION STELARA®
Bezeichnung des Arzneimittels: STELARA® 45 mg bzw. 90 mg Injektionslösung in einer
Fertigspritze. Qualitative und quantitative Zusammensetzung: Jede Fertigspritze für den
Einmalgebrauch enthält 45 mg Ustekinumab in 0,5 ml bzw. 90 mg Ustekinumab in 1 ml.
Ustekinumab ist ein rein humaner monoklonaler IgG1κ-Antikörper gegen Interleukin (IL)-12/23,
der unter Verwendung rekombinanter DNA-Technologie in einer murinen Myelomzelllinie
produziert wird. Sonstige Bestandteile: Sucrose, Histidin, Histidinhydrochlorid-Monohydrat,
Polysorbat 80, Wasser für Injektionszwecke. Anwendungsgebiete: Plaque-Psoriasis: STELARA®
ist für die Behandlung erwachsener Patienten mit mittelschwerer bis schwerer Plaque-
Psoriasis indiziert, bei denen andere systemische Therapien einschließlich Ciclosporin,
Methotrexat (MTX) oder PUVA (Psoralen und Ultraviolett A) nicht angesprochen haben,
kontraindiziert sind oder nicht vertragen wurden. Psoriatische Arthritis (PsA): STELARA® ist
allein oder in Kombination mit MTX für die Behandlung der aktiven psoriatischen Arthritis
bei erwachsenen Patienten indiziert, wenn das Ansprechen auf eine vorherige Therapie mit
nicht-biologischen krankheitsmodifizierenden Antirheumatika (DMARDs) unzureichend
gewesen ist. Gegenanzeigen: Überempfindlichkeit gegen den Wirkstoff oder einen
der sonstigen Bestandteile. Klinisch relevante, aktive Infektion (z. B. aktive Tuberkulose).
Inhaber der Zulassung: Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse,
Belgien. Verschreibungspflicht/Apothekenpflicht: Rezept- und apothekenpflichtig. ATCCode: L04AC05. Weitere Angaben zu Warnhinweisen und Vorsichtsmaßnahmen für die
Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstigen Wechselwirkungen,
Schwangerschaft und Stillzeit sowie Nebenwirkungen entnehmen Sie bitte der veröffentlichten
Fachinformation. EAP 109076
PHAT/STE/1213/0004
Table of Contents
Table of Contents
WELCOMING WORDS – ORGANISING COMMITTEE
3
GENERAL INFORMATION
5
REGISTRATION 10
NETWORKING EVENTS
11
SCIENTIFIC PROGRAMME INFORMATION
12
SCIENTIFIC PROGRAMME
15
ACCEPTED ABSTRACTS
19
COMMERCIAL EXHIBITION/SPONSORSHIP
42
INDUSTRY-SUPPORTED SESSIONS
44
VIENNA, November 19 – 21, 2014
1
dedicated to innovation
exceptionalscience
gh
ro
u
th
cr
ea
tin
g
ne
w
po
ss
ib
ili
tie
MedImmune leads a movement that demands more
out of medicine. With one of the largest and most
robust pipelines in the industry, we pioneer the future
of science — creating advancements in biotechnology
that have a true impact on health.
sc
ie
nc
e.

s
2
www.medimmune.com
© 2014 MedImmune. All rights reserved.
LOOK INSIDE THE CELL FOR A NEW PERSPECTIVE
DISCOVER THE ROLE OF
PDE4 IN PSORIASIS AND
PSORIATIC ARTHRITIS
PDE4 promotes the dysregulation of pro- and anti-inflammatory
mediators thought to occur in inflammatory disease1,2 and is present in
key inflammatory cells implicated in psoriasis and psoriatic arthritis.2-4
PDE4, phosphodiesterase-4; AMP, adenosine monophosphate; cAMP, cyclic AMP.
References: 1. Houslay MD, et al. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10(22):1503–1519.
2. Press NJ and Banner KH. PDE4 inhibitors – a review of the current field. In: Lawton G, Witty DR, eds. Progress in Medicinal Chemistry.
Amsterdam, The Netherlands: Elsevier; 2009:37–74. 3. Lowes MA, et al. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–873.
4. Veale DJ, et al. Immunopathology
of psoriasis and psoriatic
Ann Rheum
Dis. 2005;64(suppl
2):ii26–ii29.
Inflammatory
Skinarthritis.
Disease
Summit
2014
© 2014 Celgene Corporation Date of Preparation October 2014 AP/1037/08102014
PDE4
AMP
cAMP
Welcoming Words – Organising Committee
Dear participants,
it is an honor and our great pleasure to welcome you to the “Inflammatory Skin Disease
Summit 2014 – The Translational Revolution”!
In the past decade, we have experienced a veritable breakthrough in the management
of inflammatory skin diseases, which were previously lacking satisfactory treatments.
This revolution is particularly evident with the introduction of novel targeted therapies
for key inflammatory skin diseases such as psoriasis, atopic dermatitis and few other
inflammatory conditions. This translational revolution stems from a growing knowledge
of pathogenic pathways, and the advent of new technologies that are directly applicable to human biologic substrates. These ultimately led to the development of narrow
therapeutics, and to their testing in clinical trials, further amplifying our current disease
understanding.
Under the patronage of the Austrian Academy of Sciences, we have taken the initiative
to organise a symposium entitled „Inflammatory Skin Disease Summit: The Translational
Revolution“ that directly addresses and describes this new development.
We aim to deliver an outstanding meeting to our participants including plenary lectures
given by world leaders in their fields, poster sessions, oral presentations of selected
abstracts and, most importantly, a vivid discussion in the lecture hall, in front of the many
posters, and during our social events.
We want to thank all participants who have decided to join us for what we hope will be
a scientifically most stimulating event, all invited speakers and poster presenters for
sharing their work with us, our generous sponsors, and all the helping hands making this
meeting possible.
We very much hope that you will enjoy this symposium in the historic center of Vienna.
With kind regards,
James G. Krueger,
M.D., Ph.D.
Emma Guttman-Yassky,
M.D., Ph.D.
Georg Stingl,
M.D.
Patrick M. Brunner,
M.D.
3
Maurer M, et al., Hautarzt 2013 . 64:638-643
vereinfachte Darstellung der Urticaria Guidelines: 1-fach Dosierung
eines H1-AH, danach bis zu 4-fach Dosierung, danach Omalizumab als
eine von 3 Alternativen (Omalizumab, Cyclosporin A, Montelukast)
Datum der Erstellung: 9/2014 | AT1405204277
*
1
Prescribing Information see page 45
ZEIT FÜR VERÄNDERUNG
BEI CHRONISCH SPONTANER
URTIKARIA / csU
4
1— 4 — OMA
1,*
General Information
General Information
ORGANISING COMMITTEE
James G. Krueger, M.D., Ph.D.
Director, Milstein Medical Research Program
Senior Attending Physician
D. Martin Carter Professor in Clinical Investigation
Laboratory of Investigative Dermatology
The Rockefeller University, N.Y., USA
Emma Guttman-Yassky, M.D., Ph.D.
Assoc. Professor of Dermatology & Immunology
Director, Center for Excellence in Eczema and Occupational/Contact Dermatitis
Director, Laboratory of Inflammatory Skin Diseases
Icahn School of Medicine at Mount Sinai Hospital, N.Y., USA
Georg Stingl, M.D.
Professor and Chairman
Div. of Immunology, Allergy and Infectious Diseases
Dpt. of Dermatology
Medical University of Vienna, Austria
Patrick M. Brunner, M.D.
Div. of Immunology, Allergy and Infectious Diseases
Dpt. of Dermatology
Medical University of Vienna, Austria
5
6
General Information
PROFESSIONAL CONGRESS ORGANISER, SCIENTIFIC SECRETARIAT
& ACCOMMODATION BOOKING
Mondial Congress & Events
Operngasse 20b, 1040 Vienna, Austria
Phone: +43 1 58804-0
Fax: +43 1 58804 185
E-mail: isds2014@mondial-congress.com
COMMERCIAL EXHIBITION / SPONSORSHIP
MAW-Medizinische Ausstellungs- und Werbegesellschaft
Mrs. Ingrid Winkler
Mag. Michael Schneider
Freyung 6/3/3, 1010 Vienna, Austria
Phone: +43 1 536 63 33 or +43 1 536 63 82
Fax: +43 1 536 63 61
E-mail: ingrid.winkler@media.co.at or michael.schneider@media.co.at
CONGRESS VENUE
Austrian Academy of Sciences
Dr. Ignaz Seipel-Platz 2
1010 Vienna, Austria
HOW TO GET TO THE CONGRESS VENUE USING PUBLIC TRANSPORTATION
The closest underground stations are:
U1/U3 Stephansplatz
General Information
U3 Stubentor
U1/U4 Schwedenplatz
7
General Information
A treasure trove of fascinating
and richly illustrated information
History of
Allergy
Chemical Immunology and Allergy
Editors: J. Ring, K. Blaser, M. Capron, J.A. Denburg,
S.T. Holgate, G. Marone, H. Saito
Vol. 100
History of
Allergy
Editors
Edited by
K.-C. Bergmann
J. Ring
Karl-Christian Bergmann Berlin
Johannes Ring Munich
O
6
7
4
5
1
8
Chromone
This book presents a detailed and
varied historical overview of the field of
allergology. Special highlights are the
personal reflections of and interviews
with a number of pioneers in allergy,
including F. Austen, J. Bienenstock,
K. Blaser, A. de Weck, A.W. Frankland,
K. Ishizaka, and many more.
Chemical Immunology and Allergy, Vol. 100
History of Allergy
Editors: Bergmann K.-C. (Berlin), Ring J. (Munich)
XX + 426 p., 257 fig., 127 in color, 20 tab.,
hard cover, 2014
ISBN 978–3–318–02194–3
e-ISBN 978–3–318–02195–0
CHF 115.00 / EUR 96.00 / USD 135.00 (hard cover)
3
2
O
Section Titles
• Allergy through 20 Centuries
• Most Common Allergic Diseases:
Historical Reflections in Understanding
• Mechanisms of Allergy:
Important Discoveries
• Detection of Environmental Influences
and Allergens
• Progress in Allergy Management
• Pioneers of Allergy: Personal Reflections
• Allergy Societies and Collections
• Online Supplementary Material
View free sample chapters
and order your copy at
www.karger.com/chial
S. Karger AG, P.O. Box, 4009 Basel (Switzerland)
f: +41 61 306 12 34, e: orders@karger.com
KI 14253_A5
8
General Information
CLOAKROOM
A cloakroom and luggage storage facilities will be available next to the Registration
Counters on the ground floor.
SMOKING AREA
Thank you for not smoking inside the congress venue. Smoking areas can be found
outside the main entrance.
WIFI
Free WIFI is available. Please ask at the registration desk for username and password.
VENUE
Ground floor
First floor
9
10
Registration
Registration
The registration area is located on the ground floor. The Mondial Congress & Events team
as well as the congress hostesses will be pleased to help you with any inquiries. Please
do not hesitate to approach the team members if there is anything they can do to make
your stay more enjoyable.
REGISTRATION HOURS
Wednesday, November 19, 2014
Thursday, November 20, 2014
Friday, November 21, 2014
10:00 – 19:00
07:30 – 19:00
08:00 – 11:00
ONSITE REGISTRATION FEES
Delegate
EUR 250,00
Student/Trainee/Fellow
EUR 150,00
The participants’ registration fee includes:
——
——
——
——
——
——
——
——
Admission to all scientific sessions
Admission to scientic poster area and commercial exhibition
Congress materials (congress bag, final programme, badge, abstract book)
Certificate of attendance
Coffee breaks
Opening Ceremony & Welcome Reception on Wednesday, November 19, 2014
Reception on Thursday, November 20, 2014 from 18:30 – 20:00
Industry supported sessions
PAYMENT DETAILS
Please note that all onsite payments need to be made in cash or by credit card (Visa,
Mastercard, American Express, Diners Club will be accepted) in EURO only.
We cannot accept traveller’s cheques, other credit cards, Euro cheques or other currencies.
Networking Events
Networking Events
WELCOME RECEPTION & POSTER VIEWING
Wednesday, November 19, 2014, 18:30 – 21:00
Location: Exhibition & Poster Area – Ground Floor
Enjoy the Welcome Reception in the Exhibition & Poster Area with drinks and a “flying
buffet”.
POSTER VIEWING & DRINKS
Thursday, November 20, 2014, 18:30 – 20:00
Location: Exhibition & Poster Area – Ground Floor
During poster viewing, drinks will be offered.
LUNCH
Lunchboxes will be provided by Regeneron and Sanofi on Thursday, November 20, 2014
at 12:00 on the first floor.
COFFEE BREAKS
Coffee, tea, juice, water, fruit and pastries & cake will be offered during coffee breaks in
the Exhibition Area on the ground floor.
Coffee breaks are scheduled as follows:
——
——
——
——
16:20 – 17:00
10:00 – 10:30
15:30 – 17:00
10:00 – 10:30
sponsored by Pfizer
11
12
Scientific Programme Information
OPENING HOURS – SPEAKERS’ PREVIEW CENTER
The Speakers‘ Preview Center is located on the first floor in room “Johannessaal”. The
opening hours are as follows:
12:00 – 19:00
07:30 – 19:00
08:00 – 10:30
PRESENTATION GUIDELINES
1. Please locate the session room in due time. Please be at the session room at least
15 minutes prior to the start of the session.
2. Speakers should deliver and view/check their PowerPoint presentations at the
Speakers‘ Preview Center (room „Johannessaal“) at least 2 hours prior to the start
of the respective session. For sessions starting at 08:30, the PowerPoint presentation should be delivered the previous day.
In order to avoid any delays, speakers are kindly requested to hand in their PowerPoint
presentations on USB. If you bring your own laptop, the presentation will be transferred
onsite in the Preview Centre.
Please do not take PowerPoint presentations directly to the technical assistant in the
Session rooms.
CHAIRPERSON GUIDELINES
Please locate your session room in due time. Please be at the session room at least 15
minutes prior to the start of the session. We may remind you that speakers need to
strictly stick to the time schedule.
POSTERS
The poster area is located on the ground floor. Each poster will be displayed for the entire
duration of the congress. Posters have to be mounted on Wednesday, November 19
between 11:00 and 15:00. Please attach the poster to the board with the corresponding poster placement number and remove it on Friday, November 21, 2014 until 10:30.
Otherwise our staff will remove it.
ABSTRACT BOOK
A printed abstract book will be provided in your congress bag. Moreover, the abstracts will
be published in the Journal “Experimental Dermatology”.
TRAVEL FELLOWSHIPS
Travel Fellowships need to be picked up at the registration desk on Thursday, November
20, 2014 from 10:00 – 12:00.
INVITED SPEAKERS
Masayuki Amagai
Robert Bissonnette
Anne Bowcock
Angela M. Christiano
Alexander Enk
Kilian Eyerich
Lars French
Richard Gallo
Michel Gilliet
Emma Guttman-Yassky
Muzlifah Haniffa
Thomas Jung
James G. Krueger
Thomas S. Kupper
Thomas Luger
Marcus Maurer
Frank Nestle
Jean-Francois Nicolas
Kristian Reich
Martin Röcken
Martin Steinhoff
Georg Stingl
Peter van de Kerkhof
Wolfgang Weninger
Tokyo, Japan
Montreal, Canada
London, United Kingdom
New York City, NY, USA
Heidelberg, Germany
Munich, Germany
Zurich, Switzerland
San Diego, CA, USA
Lausanne, Switzerland
Newcastle, United Kingdom
Zurich, Switzerland
Boston, MA, USA
Münster, Germany
Berlin, Germany
London, United Kingdom
Lyon, France
Hamburg, Germany
Tübingen, Germany
Dublin, Ireland
Vienna, Austria
Amsterdam, The Netherlands
Sydney, Australia
13
14
SESSION CHAIRS
Patrick Brunner
Enno Christophers
Kevin Cooper
Dean Mann
Stefanie Eyerich
Mayumi Fujita
Emma Guttman-Yassky
Conrad Hauser
Emmilia Hodak
Sarolta Karpati
Christine Neumann
Graham Ogg
Luis Puig
Nikolaus Romani
Annika Scheynius
Erwin Tschachler
Rudolf Valenta
Klaus Wolff
Vienna, Austria
Kiel, Germany
Cleveland, OH, USA
Baltimore, MD, USA
Munich, Germany
Aurora, CO, USA
Geneva, Switzerland
Petah Tiqva, Israel
Budapest, Hungary
Cologne, Germany
Oxford, United Kingdom
Barcelona, Spain
Innsbruck, Austria
Stockholm, Sweden
Vienna, Austria
Vienna, Austria
Vienna, Austria
Transforming the language
of life into vital medicines
At Amgen, we believe that the answers to medicine's most
pressing questions are written in the language of our DNA.
As pioneers in biotechnology, we use our deep understanding of
that language to create vital medicines that address the unmet
needs of patients fighting serious illness – to dramatically
improve their lives.
For more information about Amgen, our pioneering science
and our vital medicines, visit www.amgen.com.
Amgen is proud to support
the Inflammatory Skin
Disease Summit 2014
Amgen Europe GmbH, Dammstrasse 23, CH-6301 Zug
©2014 Amgen Inc. All rights reserved.
AMG-IHQ-AMG-613-2014-October-NP/AMG-AUT-AMG-801-2014-October-NP
Scientific Programme
WEDNESDAY, NOVEMBER 19, 2014
Clinical afternoon – Trailblazing the clinical trial landscape
Chairs: Enno Christophers (Kiel, Germany), Klaus Wolff (Vienna, Austria)
(Kindly supported by Boehringer Ingelheim)
15.00 – 15.20 Upcoming trials in psoriasis
Peter van de Kerkhof (Nijmegen, The Netherlands)
15.20 – 15.40 Can treatment of inflammatory skin diseases improve
systemic inflammation?
Robert Bissonnette (Montreal, Canada)
15.40 – 16.00 IgE-specific immune-absorption in adult patients with severe
atopic dermatitis
Kristian Reich (Hamburg, Germany)
16.00 – 16.20 Rosacea – Pathogenesis and new treatments
Martin Steinhoff (Dublin, Ireland)
16:20 – 17:00 Coffee Break
Opening
Chairs: Emma Guttman-Yassky (New York City, NY), Patrick Brunner (Vienna, Austria)
17.00 – 17.30 Opening & Welcome
Georg Stingl (Vienna, Austria)
17.30 – 17.45 Setting the stage
Georg Stingl (Vienna, Austria)
17.45-18.15
Skin Associated Lymphoid Tissue Revisited
Thomas S. Kupper (Boston, MA)
18.15-18.45
Inflammatory skin diseases – The technological revolution
James G. Krueger (New York City, NY)
18.45-21:00
Reception and poster viewing
15
16
THURSDAY, NOVEMBER 20, 2014
Morning lectures: Cellular and molecular circuits in cutaneous inflammation
Chairs: Nikolaus Romani (Innsbruck, Austria), Erwin Tschachler (Vienna, Austria)
08:30 – 09.00 Mediators of inflammation
Thomas Luger (Münster, Germany)
09.00 – 09:30 Innate immunity and dendritic cells
Michel Gilliet (Lausanne, Switzerland)
09:30 – 10:00 AMPs and the microbiome
Richard Gallo (San Diego, CA)
10.00 – 10:30 Coffee break
Chairs: Dean Mann (Baltimore, MD), Graham Ogg (Oxford, United Kingdom)
10:30 – 11.00 The inflammasome and autoinflammation
Lars French (Zurich, Switzerland)
11.00 – 11:30 Antigen presentation in the skin
Muzlifah Haniffa (Newcastle, United Kingdom)
11:30 – 12.00 Lymphocytes – The family is growing
Wolfgang Weninger (Sydney, Australia)
12:00 – 14.00 Sponsored lunch symposium (Regeneron and Sanofi)
14.00 – 14.30
Oral presentations from selected abstracts
Chairs: Mayumi Fujita (Aurora, CO); Emmilia Hodak (Petah Tiqva, Israel)
P001 Rosacea is more than skin deep: Patients have higher odds of
having chronic systemic diseases in a skin severity-dependent
manner
B. M. Rainer1, A. H. Fischer1, D. Luz Felipe da Silva1, S. Kang1, A. L. Chien1
1Department of Dermatology, Johns Hopkins School of Medicine, Baltimore,
Maryland, USA
P002 Targeting the IFN-γ-CXCL10 axis in keratinocytes to develop novel
treatments for vitiligo
J. M. Richmond1, K. Essien1, S. Currimbhoy2, A. Pandya2, D. Bangari3, M. Youd3,
J. R. Groom4, A. D. Luster5, J. E. Harris1
1Division of Dermatology, Department of Medicine, University of Massachusetts
Medical School, Worcester, MA, USA
2Department of Dermatology, University of Texas Southwestern Medical Center,
Dallas, TX, USA
3Genzyme, a Sanofi Corporation, Framingham, MA, USA
4
Walter and Eliza Hall Institute of Medical Research & University of Melbourne,
Melbourne, Australia
5
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
P003 Epidermal Tissue-Resident Memory T cells Form a Localised
Memory in Clinically Healed Psoriasis
S. S. H. Cheuk1, M. Ståhle1, L. Eidsmo1
1Dermatology and Venerology Unit / Department of Medicine / Solna / Karolinska
Institutet, Stockholm, Sweden
Afternoon lectures: Mechanisms of disease – Autoimmunity
Chairs: Stefanie Eyerich (Munich, Germany), Annika Scheynius (Stockholm, Sweden)
14.30 – 15.00 Therapeutic polarization of the immune response
Martin Röcken (Tübingen, Germany)
15.00 – 15.30 IVIG in dermatology
Alexander Enk (Heidelberg, Germany)
15.30 – 17.00 Sponsored symposium (Pfizer)
Chairs: Sarolta Karpati (Budapest, Hungary), Kevin Cooper (Cleveland, OH)
17.00 – 17.30 Chronic urticaria
Marcus Maurer (Berlin, Germany)
17.30 – 18.00 Towards antigen-specific immune suppression in pemphigus
Masayuki Amagai (Tokyo, Japan)
18.00 – 18.30 Alopecia areata – Pathogenesis and possible treatments
Angela Christiano (New York City, NY)
18.30 – 20:00 Drinks and poster viewing
17
18
FRIDAY, NOVEMBER 21, 2014
Morning lectures: Mechanisms of disease – The complex interactions between
the genetic, immune and barrier interphase in eczema and psoriasis
Chairs: Rudolf Valenta (Vienna, Austria), Luis Puig (Barcelona, Spain)
08.30 – 09.00 Systems biology, biomarkers, and predictive medicine
Frank O. Nestle (London, United Kingdom)
09.00 – 09.30 The genetics and epigenetics of psoriasis and atopic dermatitis
Anne Bowcock (London, United Kingdom)
09.30 – 10.00 Irritant and allergic contact dermatitis and drug allergy –
Pathogenesis and therapeutic implications
Jean-Francois Nicolas (Lyon, France)
10.00 – 10.30 Coffee break
Chairs: Christine Neumann (Cologne, Germany), Conrad Hauser (Geneva, Switzerland)
10.30 – 11.00 Cross talk between T-cell subsets and implications for
inflammatory skin diseases
Kilian Eyerich (Munich, Germany)
11.00 – 11.30 Evolving concepts in atopic dermatitis and implications for
targeted therapeutics
Emma Guttman-Yassky (New York City, NY)
11.30 – 12.00 From target discovery to therapeutic development
Thomas Jung (Zurich, Switzerland)
Accepted Abstracts
Accepted Abstracts
All abstracts will be published in the Journal “Experimental Dermatology” and a printed
abstract book will be provided in your congress bag.
P001
Rosacea is more than skin deep: Patients have higher odds of
having chronic systemic diseases in a skin severity-dependent
manner
B. M. Rainer1, A. H. Fischer1, D. Luz Felipe da Silva1, S. Kang1, A. L. Chien1
1Department of Dermatology, Johns Hopkins School of Medicine, Baltimore,
Maryland, USA
P002
Targeting the IFN-γ-CXCL10 axis in keratinocytes to develop novel
treatments for vitiligo
J. M. Richmond1, K. Essien1, S. Currimbhoy2, A. Pandya2, D. Bangari3, M. Youd3,
J. R. Groom4, A. D. Luster5, J. E. Harris1
1Division of Dermatology, Department of Medicine, University of Massachusetts
Medical School, Worcester, MA, USA
2Department of Dermatology, University of Texas Southwestern Medical Center,
Dallas, TX
3Genzyme, a Sanofi Corporation, Framingham, MA, USA
4
Walter and Eliza Hall Institute of Medical Research & University of Melbourne,
Melbourne, Australia
5
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
P003
Epidermal Tissue-Resident Memory T cells Form a Localised
Memory in Clinically Healed Psoriasis
S. S. H. Cheuk1, M. Ståhle1, L. Eidsmo1
1Dermatology and Venerology Unit / Department of Medicine / Solna / Karolinska
P004
IL-17A induces inflammation-associated gene products in blood
monocytes and treatment with ixekizumab reduces their
expression in psoriasis patient blood
C. Wang1, M. Suarez-Farinas1, K. Nograles1, C. Abrantes Mimoso1, D. Shrom2,
E. Dow2, M. P. Heffernan2, R. W. Hoffman2, J. G. Krueger1
1Rockefeller University, New York, USA
2Eli Lilly, Indianapolis, USA
19
20
Accepted Abstracts
P005
Specific roles for dendritic cell subsets during initiation and
progression of psoriasis
E. Glitzner1, A. Korosec1, P. M. Brunner2, B. Drobits1, N. Amberg1, H. B. Schonthaler3,
T. Kopp2, E. F. Wagner3, G. Stingl2, M. Holcmann1, M. Sibilia1
1Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer
Center, Medical University of Vienna, Vienna, Austria
2Department of Dermatology, Division of Immunology, Allergy and Infectious
Diseases, Medical University of Vienna, Vienna, Austria.
3BBVA Foundation–CNIO Cancer Cell Biology Programme, Spanish National
Cancer Research Centre (CNIO), Madrid, Spain
P006
Successful use of ustekinumab therapy in refractory severe atopic
dermatitis
Y. Mansouri1, A. Shroff1, E. Guttman1
1Icahn School of Medicine at Mount Sinai, New York, USA
P007
Low dose inhalation of Interleukin-2 (IL-2) bio-chemotherapy for
the treatment of pulmonary metastases in melanoma patients
C. Posch1,2, F. Weihsengruber1, K, Bartsch1, V. Feichtenschlager1, M. Sanlorenzo2,3,
I. Vujic1, B. Monshi1, S. Ortiz-Urda2, K. Rappersberger1
1The Rudolfstiftung Hospital, Academic Teaching Hospital, Medical University
Vienna, Department of Dermatology, Vienna, Austria
2University of California San Francisco, Department for Dermatology, Mt. Zion
Cancer Research Center, San Francisco, USA
3Department of Medical Sciences, Section of Dermatology, University of Turin,
Turin, Italy
P008
Hyper IgE (Job Syndrome) with abdominal aortic aneurysm and
leucoma corneae
B. Kotevska1, Z. Demerdzhieva1, R. Darlenski1, N. Tsankov1
1Tokuda Hospital, Sofia, Bulgaria
P009
Identification of TSLP-responsive dermal DC in murine skin
hypersensitivity models
S. Ochiai1, B. Roediger2, E. Shklovskaya2, B. Fazekas de St Groth2, H. Yamane3,
W. Weninger2, G. Le Gros1, F. Ronchese1
1Malaghan Institute of Medical Research, Wellington, New Zealand
2Centenary Institute, Sydney NSW, Australia
3National Institutes of Health, Bethesda, MD, USA
Accepted Abstracts
P010
Cryopyrin-associated Periodic Syndrome Caused by a Novel
Mutation in the NLRP3 Gene
V. Mateeva1, M. Kadurina1
1Department of Dermatovenerology and Allergology; Military Medical Academy,
Sofia, Bulgaria
P011
Comparison of negative immune regulators between a prototypic
delayed-type hypersensitivity reaction induced by diphencyprone
and psoriasis vulgaris: potential insights into chronic inflammation
N. Gulati1, M. Suárez-Fariñas1, J. Correa da Rosa1, J. G. Krueger1
1The Rockefeller University, New York, USA
P012
Skin response to a carcinogen involves the xenobiotic receptor
pregnane X receptor
A. Elentner1, D. Ortner1, F. Sparber1, S. Ebner2, B. Del Frari3, F. J. Gonzalez4,
P. M. Fernández-Salguero5, M. Schmuth1, S. Dubrac1
1Department of Dermatology and Venereology, Innsbruck Medical University,
Innsbruck, Austria.
2VTT Daniel Swarovski Laboratory, Department of Surgery, Innsbruck Medical
University, Innsbruck, Austria
3Department of Plastic, Reconstructive and Esthetic Surgery, Innsbruck Medical
4
Laboratory of Metabolism, Center for Cancer Research, National Cancer
Institute, National Institutes of Health, Bethesda, Maryland, USA
5
Department of Biochemistry, Molecular Biology and Genetics, Faculty of
Sciences, University of Extremadura, Badajoz, Spain
P013
Dissection of Inflammatory Pathways and Molecular Trajectories of
Multiple Therapeutics
C. Russel1, R. Hu1, J. Bigler1, M. Boedigheimer2, B. Sullivan2, G. Kricorian2, P. Klekotka2,
J. Chung2, K. Newhall1, D. Martin1
1Amgen Inc., Seattle WA, USA
2Amgen Inc., Thousand Oaks, CA, USA
21
Regeneron and Sanofi:
22
Accepted Abstracts
A scientific collaboration focused on the disco
fully human monoclonal antibodies.
An investigational drug is in development
fully-human monoclonal antibody specific
moderate-to-severe atopic dermatitis.
3 Phase 2b: completed
3 Phase 3 clinical studies: on-g
Regene
the Inf
The investigational agent described above is current
been evaluated for approval by any regulatory author
© 2014, Regeneron Pharmaceuticals, Inc. and Sanofi.
ILF-0224/SAGLB.DUP.14.10.0326
Accepted Abstracts
23
overy and development of targeted
as a subcutaneously-administered,
c for the IL-4Rα subunit for uncontrolled
going
CLINICAL TRIAL PROGRAM
IN ATOPIC DERMATITIS
eron and Sanofi are proud sponsors of
flammatory Skin Disease Summit 2014
tly under clinical development, and the safety and efficacy have not
rity.
All rights reserved
10/2014
24
Accepted Abstracts
P014
Differential DNA methylation and microRNA expression in
skin-homing CLA+ T cells of atopic eczema patients
A. Scheynius1, N. Acevedo1,2, S. Bruhn1, A. Andersson1, G. Wikberg3, L. Lundeberg3,
C. Söderhäll2, J. Kere2, D. Greco4
1Department of Medicine Solna, Translational Immunology Unit, Karolinska
2Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm,
Sweden
3
Dermatology and Venereology Unit, Karolinska University Hospital, Stockholm,
Sweden
4
Finnish Institute of Occupational Health, Systems Toxicology Team, Helsinki,
Finland
P015
CD90+ dermal stromal cells induce an immunosuppressive
environment via the induction of regulatory T cells in vitro
K. Pfisterer1, K. M. Lipnik2, E. Hofer2, A. Elbe-Bürger1
Diseases, Laboratory of Cellular and Molecular Immunobiology of the Skin,
Medical University of Vienna, Vienna, Austria
2Department of Vascular Biology and Thrombosis Research, Medical University of
Vienna, Vienna, Austria
P016
Skin inflammation in the absence of adaptive immunity
Ö. Uluçkan1, J. Schnabl1, E. F. Wagner1
1BBVA-Foundation–CNIO Cancer Cell Biology Program, Spanish National Cancer
Research Centre (CNIO), Madrid, Spain
P017
Issues of autoimmunity and autoinflammation in pemphigus,
bullous pemphigoid and dermatitis herpetiformis: Comparison of
cutaneous pathogeneses
J. Gornowicz-Porowska1, M. Bowszyc-Dmochowska1, P. Pietkiewicz1,
A. Seraszek-Jaros2, E. Kaczmarek2, M. Dmochowski1
1Department of Dermatology, Poznan University of Medical Sciences, Poznan,
Poland
2Department of Bioinformatics and Computational Biology, Poznan University of
Medical Sciences, Poznan, Poland
P018
Ultraviolet B generates Type 1 Interferon and induces
autoantibody-mediated disease in a mouse model of cutaneous
lupus
C. Sontheimer1,2, K. Elkon1
1University of Washington, Seattle, USA
2Seattle Children‘s Hospital, Seattle, USA
Accepted Abstracts
P019
The Use of the 308-nm Excimer Laser for the Treatment of Chronic
Hand and Foot Eczema
A. Shroff1, D. Malajian2, S. Rose1, D. Bernstein1, G. Singer1, M. Lebwohl1, S. Hadi1,
E. Guttman-Yassky1
1Icahn School of Medicine at Mount Sinai, New York, USA
2Columbia University, College of Physicians and Surgeons, New York, USA
P020
WITHDRAWN
P021
Methylation-induced silencing of the inflammasome adaptor
protein ASC in human cutaneous squamous cell carcinoma and its
diametric role in inflammation and proliferation
K. Meier1, K. Welsch1, F. C. Eberle1, S. K. Drexler2, A. S. Yazdi1
1Department of Dermatology, Eberhard-Karls-University Tuebingen, Germany
2Department of Biochemistry, University of Lausanne, Switzerland
P022
The contribution of myeloid cells to Epidermal Growth Factor
mediated immune homeostasis in the skin
M. Holcmann1, M. Amberg1, B. Lichtenberger2, P.A. Gerber3, M. Sibilia1
1Inst. of Cancer Research; Dept. of Medicine I; Medical University of Vienna,
Vienna, Austria
2Centre for Stem Cells and Regenerative Med.; Div. of Genetics; King‘s College,
London, Great Britain
3Dept. of Dermatology; University of Düsseldorf, Düsseldorf, Germany
P023
Transcriptomic and lipidomic profiling of eicosanoid/docosanoid
signalling in affected and non-affected skin of human atopic
dermatitis patients
J. Mihály1, C. Weise2, A. Barsony1, J. Gericke1*, M. Worm2, R. Rühl1,3
1Department of Biochemistry and Molecular Biology, University of Debrecen,
Hungary
2Allergy-Center-Charité, Department of Dermatology and Allergology,
Charité – Universitätsmedizin, Berlin, Germany
3Paprika Bioanalytics BT, Debrecen, Hungary
*Allergy-Center-Charité, Department of Dermatology and Allergology,
Charité – Universitätsmedizin, Berlin, Germany (present address).
25
26
Accepted Abstracts
P024
Mannan induces ROS-regulated, IL-17A–dependent psoriasis
arthritis-like disease in mice
I. Khmaladze1, T. Kelkka1, S. Guerard1,2,3, K. Wing1, A. Pizzolla1, A. Saxena1,
K. Lundqvist4, M. Holmdahl4, K. Selva Nandakumar1, R. Holmdahl1,3
1Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm,
Sweden
2Turku Doctoral Programme of Biomedical Sciences, Turku, Finland
3Medical Inflammation Research, Medicity Research Lab, University of Turku,
Turku, Finland
4
Department of Clinical Dermatology and Venereology, University Hospital, Lund,
Sweden
P025
The Patient Burden of Atopic Dermatitis: Insights from a Dupilumab
Phase 2 Clinical Trial in Adults With Moderate-to-Severe Disease
V. Mastey4, E. Simpson1, T. Bieber2, L. Eckert3, R. Wu4, M. Ardeleanu4, N. Graham4,
G. Pirozzi5, E.R. Sutherland6
1Oregon Health Sciences University, Portland Oregon, USA
²University of Bonn, Bonn, Germany
3Sanofi, Paris, France
4
Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
5
Sanofi, Bridgewater, New Jersey, USA
6
Sanofi, Cambridge, Massachusetts, USA
P026
Persistence of Biologic Therapy in Psoriatic Disease: Results from
the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
A. Menter1, K. Rapp2, G. Krueger3, M. Augustin4, F. Kerdel5, M. Gooderham6,
K. Goyal7, S. Fakharzadeh7, W. Langollf7, J.Sermon8, S. Calabro7, D. Pariser9
1Baylor University Medical Center, Dallas, USA
2Probity Medical Research, Waterloo, Canada
3University of Utah, Utah, USA
4
University Clinics of Hamburg, Hamburg, Germany
5
Florida Academic Dermatology Center, Miami, USA
6
SKIN Centre for Dermatology and Probity Medical Research, Peterborough,
Canada
7
Janssen Scientific Affairs LLC, Pennsylvania, USA
8
Jannsen-Cilag, Beerse, Belgium
9
Eastern Virginia Medical School and Virginia Clinical Research Inc, Virginia, USA
Accepted Abstracts
P027
Malignancies in the psoriasis longitudinal assessment and registry
(PSO-LAR) study: Current status of observations
D. Fiorentino1, M. Lebwohl2, V. Ho3, R. Langley4, K. Goyal5, S. Fakharzadeh5,
S. Calabro5, W. Lanholff5
1Stanford University, Stanford, USA
2Mount Sinai Medical Center, New York, USA
3University of British Columbia, Vancouver, Canada
4
Dalhousie University, Halifax, Nova Scotia, Canada
5
Janssen Scientific Affairs, LLC., Horsham, USA
P028
Alterations in immune-modulating analytes in skin wash fluid from
healthy elderly subjects
K. A. Brogden2, C. L. Fischer2, J. A. Fairley3, N. K. Brogden1
1University of Iowa College of Pharmacy, Department of Pharmaceutical
Sciences, Iowa City, USA
2University of Iowa College of Dentistry, Dows Institute for Dental Research,
Iowa City, USA
3University of Iowa College of Medicine, Department of Dermatology, Iowa City,
USA
P029
Persistent inflammation impairs wound healing in a new preclinical
porcine ulcer model
B. Liehl1, H. Fahrngruber1, V. Gruber1, M. Pillinger1, K. Jahn-Bassler2, W. Bauer2,
G. Stingl2, F. Kalthoff1, B. Wolff-Winiski1, E. Kriehuber1
1Novartis Institutes for Biomedical Research, Dept. of Dermatology, Vienna,
Austria
2Dept. of Dermatology (DIAID), Medical University of Vienna, Vienna, Austria
P030
Whole mount scanning for the quantitative analysis of wound
closure in an ex-vivo pig skin model
C. Vaculik1, H. Fahrngruber1, V. Gruber1, K. Johnson3, G. Li3, K. Jahn-Bassler2,
W. Bauer2, G. Stingl2, E. Kriehuber1, F. Kalthoff1, B. Wolff-Winiski1, B. Liehl1
1Novartis Institutes for Biomedical Research, Dept. of Dermatology, Vienna,
Austria
2Dept. of Dermatology (DIAID), Medical University of Vienna, Vienna, Austria
3Novartis Institutes for Biomedical Research, GNF, San Diego, USA
27
28
Accepted Abstracts
P031
Kappa-opioid receptor agonist WOL071-007 ameliorates ongoing
inflammation in mouse models of psoriasis and allergic contact
dermatitis
M. Soeberdt1, N. Sucker2, A.C. Lüdiger2, U. Knie1, D. Metze2, T.A. Luger2, K. Loser2,
C. Abels1
1Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany
2Department of Dermatology, University of Münster, Münster, Germany
P032
CD200R and the regulation of skin immune homeostasis and
inflammation
A. E. Saunders1
1Manchester Collaborative Centre for Inflammation Research, Inflammation
and Repair, Faculty of Human and Medical Sciences, University of Manchester,
Manchester, UK
P033
Human fibroblast-derived matrix production in 96-well microplates
A. P. Winiski1, S. Olt1, S. Wang1, W. Bauer2, K. Jahn2, G. Stingl2, E. Kriehuber1, B. Liehl1,
F. Kalthoff1, B. Wolff-Winiski1
1ATI/Dermatology, Novartis Institutes for BioMedical Research, Vienna, Austria
Diseases, Vienna, Austria
P034
Molecular Profiling of Alopecia Areata identifies Th1/Tc1 and Th2/
Tc2 signatures
J. Fuentes-Duculan1, M. Suarez-Farinas1, K. Bonifacio1, N. Gulati1,
E. Guttman-Yassky1, A. Shemer2, J. G. Krueger1
1Laboratory of Investigative Dermatology, The Rockefeller University, New York,
USA
2Department of Dermatology, Tel-Hashomer, Tel Aviv, Israel
P035
Filaggrin deficiency leads to Pparα downregulation and impaired
5-Lox signaling
S. Blunder1, R. Rühl2, F. Radner3, M. Schmuth1, S. Dubrac1
1Department of Dermatology, Medical University of Innsbruck, Austria
2Department of Biochemistry and Molecular Biology, University of Debrecen,
Hungary
3Department of Biochemistry, University of Graz, Austria
Accepted Abstracts
P036
Prediction of PASI75 Response in Psoriatic Patients based on gene
expression of early time points
M. Suarez – Farinas4, C. Correa-da Rosa1, S. Tian2, A. Gottlieb3, J. Krueger4
1Center for Clinical and Translational Science, Rockefeller University, New York,
USA
2Division of Clinical Epidemiology, First Hospital of Jilin University, Jilin, China
3Tufts Medical Center, Boston, USA
4
Laboratory for Investigative Dermatology, Rockefeller University, New York, USA
P037
Safety and Efficacy of AN2728 Topical Ointment, 2% and 0.5%,
in a Phase 2 Dose-Ranging Study of Adolescents with
Mild-to-Moderate Atopic Dermatitis
L. Stein-Gold1, L. Spelman2, M. Spellman3, M. Hughes4, L. Zane4
1Henry Ford Hospital, Detroit, USA
2Queensland Institute of Dermatology, Queensland, Australia
3Private Practive, San Francisco, USA
4
Anacor Pharmaceuticals Inc., Palo Alto, USA
P038
AN2728, A New Boron-Based Topical Anti-Inflammatory Agent,
Inhibits Phosphodiesterase 4 (PDE4)
Y. Freund1, C. Dong1, C. Virtucio-Frates1, F. Rock1, Y. Mak1, Y. Zhou1, L. Zane1,
K. Jarnagin1
1Anacor Pharmaceuticals, Inc., Palo Alto, USA
P039
Maximal Use Systemic Exposure (MUSE) Study Evaluating AN2728,
A Novel Boron-Based Small Molecule, for the Treatment of
Pediatric and Adolescent Subjects with Mild-to-Moderate Atopic
Dermatitis
L. Kircik1, R. Call2, E. Tschen3, Z. Draelos4, M. Van Syoc5, L. Zane5, A. Hebert6
1DermResearch, PLLC, Louisville, USA
2Clinical Research Partners, LLC, Henrico, USA
3Academic Dermatology Associates, Albuquerque, USA
4
Dermatology Consulting Services, High Point, USA
5
Anacor Pharmaceuticals Inc., Palo Alto, USA
6
Dermatology Clinical Research Unit, University of TX Health Science Center,
Houston, USA
P040
Sebopsoriasis in HIV-positive patients: Response to topical
calcineurin inhibitors
T. Tull1, M. Noy1, N. Ioannou1, C. B. Bunker1, N. Morar1
1Chelsea and Westminster NHS Trust, London, UK
29
30
Accepted Abstracts
P041
A retrospective, hospital-based study of cardiovascular risk factors
in patients with psoriasis
A. Marak1, R. Chander1
1New Delhi, India
P042
Suppression of antigen-specific adaptive immunity by IL-37 via
induction of tolerogenic dendritic cells
Y.Luo1, X. Cai1, S. Liu1, S. Wang1, C. Nold-Petry2, M. Nold2, P. Bufler3, D. Norris1,
C. Dinarello4, M. Fujita1
1Department of Dermatology, University of Colorado AMC, Aurora, USA
2The Ritchie Centre, Monash University, Melbourne, Australia
3Children’s Hospital, Ludwig-Maximilians University, Munich, Germany
4
Department of Medicine, University of Colorado AMC, Aurora, USA
P043
RNA-seq of Psoriasis Case-Control Sample Reveals Coexpression of
Coding Genes and Long Non-coding RNA Transcripts
R. Ahn1, R. Gupta1, K. Lai1, M. Dimon1, J. Pons1, W. Liao1
1University of California, San Francisco, Department of Dermatology,
San Francisco, USA
P044
Pro-osteoclastogenesis march is induced by cutaneous
pro-inflammatory mediators
A. Balato1, A. Raimondo1, S. Lembo1, M. Schiattarella1, G. Caiazzo1, R. Di Caprio1,
N. Balato1, F. Ayala1
1Department of Dermatology, University of Naples Federico II, Naples, Italy
P045
Immune signatures of psoriasis: Comparison of gene expression
profiles in psoriasis patients after therapy with biological agents
D. Kivelevitch1, M. Sharma1, B. Mansouri1, M. Patel2, C. Ryan2, A. Menter2,
G. Obermoser1
1Baylor Insitute for Immunology Research, Dallas, USA
2Menter Research Institute, Dallas, USA
P046
CD69 controls CD98-dependent L-tryptophan uptake and
AHR-mediated IL-22 secretion in psoriasis
D. Cibrián Vera1, M. Laura Saiz1, H. de la Fuente1, R. Sánchez2, I. Jorge Cerrudo2,
J. Vazquez2, C. Punzon3, M. Fresno3, P. Martin2, F. Sánchez-Madrid1,2
1Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de
Madrid, Madrid, Spain,
2Department of Vascular Biology and Inflammation, CNIC, Madrid, Spain
3Departament of Molecular Biology, Centro de Biología Molecular Severo Ochoa,
Madrid, Spain
Accepted Abstracts
P047
Circadian Rhythm and Skin Inflammation
E. Baron1, M. Lam1, A. Suggs1
1Department of Dermatology, University Hospitals, Case Western Reserve
University, Cleveland, USA
P048
Loss of K-homology type splicing regulatory protein accelerates
development of psoriasiform dermatitis in mice
I. Ahmad1, E. M. Burns1, W. Min1, C.-F. Chou2, C. A. Elmets1, C.-Y. Chen2, N. Yusuf1
1University of Alabama at Birmingham, Birmingham, USA
P049
Insights into stratification of Belimumab responsiveness:
self-reactive B cells that are not regulated by BAFF-mediated
tolerance
N. Nikbakht1, T. Manser2
1Department of Dermatology and Cutaneous Biology, Thomas Jefferson
University, Philadelphia, USA
2Department of Microbiology and Immunology, Thomas Jefferson University,
Philadelphia, USA
P050
Efficacy of intravenous immunoglobulins in livedoid vasculopathy:
Long term follow up of 11 patients
B. Monshi1, C. Posch1, I. Vuic1, A. Sesti1, S. Sobotka1, K. Rappersberger1
1 Department of Dermatology and Venerology,The Rudolfstiftung Hospital,
Teaching Hospital of Vienna Medical University, Vienna, Austria
P051
Erosive pustular dermatosis (EPDS) of the scalp – therapeutic
management with intermittent topical class-3-steroids
T. Stockinger1, B. Monshi1, K. Rappersberger1
1Department of Dermatology, Rudolfstiftung Hospital, Vienna, Austria
P052
Up-regulation of IL-10 and TGF-β in Flg-deficient skin might
prevent chronic skin inflammation
V. Moosbrugger-Martinz1, R. Gruber1,2, M. Schmuth1, S. Dubrac1
1Department of Dermatology and Venereology, Innsbruck Medical University,
Innsbruck, Austria
2Center for Dermatogenetics, Division of Human Genetics, Innsbruck Medical
P053
The role of FoxP3+ regulatory T cells in psoriasiform skin disease
K. Adelmann1,2, A.N. Hegazy1, G. Ogg2, F. Powrie1
1Experimental Medicine Division, TGU, NDM, University of Oxford, Oxford,
United Kingdom
2MRC Human Immunology Unit, RDM, WIMM, University of Oxford, Oxford,
United Kingdom
31
32
Accepted Abstracts
P054
In vivo analysis of mast cell homeostasis in the skin
B. Roediger1,2, P. L. Tong1,2,3, S. S. Tay1,2, R. Jain1,2, W. Weninger1,2,3
1Centenary Institute, Newtown, NSW, Australia
2Discipline of Dermatology, University of Sydney, Camperdown, NSW, Australia
3Department of Dermatology, Royal Prince Alfred Hospital, Camperdown, NSW,
Australia
P055
Safety and effectiveness of biologic therapy in psoriasis patients
with viral hepatitis B or C
M. Zarei1, C. Levy2, P. Romanelli1
1Department of Dermatology and Cutaneous Surgery, University of Miami,
Miller School of Medicine, Miami, Florida, USA
2Department of Hepatology, University of Miami, Miller School of Medicine, Miami,
Florida, USA
P056
SLURP-2 may be involved in the pathophysiology of psoriasis
H. Tsuji1, H. Takahashi2, T. Kumai1, H. Iizuka2, H. Kobayashi1
1Department of Immunopathology, Asahikawa Medical University, Asahikawa,
Japan
2Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan
P057
Association of novel regulatory variants in adult, chronic atopic
dermatitis
T. Pansuriya1, A. Shemer2, K. Gulewicz1, A. Quiggle1, W. Jones1, Z. Goodwin1,
E. Guttman-Yassky4, C. de Guzman Strong1
1Washington University School of Medicine, Saint Louis, USA
2Tel-Aviv University, Tel-Aviv, Israel
3Rockefeller University, New York, USA
4
Icahn School of Medicine, New York, USA
P058
CCL7 contributes to the TNF-alpha-dependent inflammation of
lesional psoriatic skin
P.M. Brunner1, E. Glitzner1, B. Reininger1, I. Klein1, G. Stary1, M. Mildner1, P. Uhrin1,
M. Sibilia1, G. Stingl1
1Medical University of Vienna, Vienna, Austria
P059
Challenging treatment of a patient with progressive severe
psoriasis and chronic HBV infection with infliximab
C. Luan1, N. Gu1, M. Zhou1, X. Yao1, X. Fan1, M. Chen1
1Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union
Medical College, Nanjing, Jiangsu, China
Accepted Abstracts
P060
Upregulation of activating Fc gamma receptors on myeloid
antigen-presenting cells in psoriasis
C. Bangert1, D. Laimer1, M. Schaschinger1, E. Kriehuber1, T. Kopp2
1Department of Dermatology, DIAID, Vienna, Austria
2Juvenis Medical Center, Vienna, Austria
P061
The role of IL-17A in the pathogenesis of Epidermolysis bullosa
acquisita
M. Wannick1, X. Yu2, Y. Iwakura3, R. Ludwig4, F. Petersen2, C. Hölscher1
1Infection Immunology, Research Center Borstel, Germany
2Biochemical Immunology, Research Center Borstel, Germany
3University of Tokyo, Japan
4
Clinical Dermatology, University Hospital Lübeck, Germany
P062
Bullous Pemphigoid: Contribution of IgE Auto-Antibodies to
Disease Pathogenesis
P. Freire1, N. Reiter1, P. Heil1, G. Stingl1
1Department of Dermatology – Division of Immunology, Allergy and Infectious
Diseases, Medical University of Vienna, Vienna, Austria
P063
Inflammatory effects of common skin microbial species on cultured
keratinocytes
P. Duckney1, H. K. Wong1, J. Serrano1, T. Oddos1, G. N. Stamatas1
1Johnson & Johnson Santé Beauté France, Issy-les-Moulienaux, France
P064
Allergic responses to common sensitizers show lower magnitude
and distinct immune polarization in atopic skin
D. Malajian1,2, A. Shemer3, J. Correa da Rosa1,4, M. Rozenblit1,5, N. Dhingra1,2, H. Xu1,
X. Zheng1, M. Suarez-Farinas1,4, J. G. Krueger1,4, E. Guttman-Yassky1,5
1Laboratory for Investigative Dermatology, Rockefeller University, New York, USA
2Columbia University College of Physicians and Surgeons, New York, USA
3Department of Dermatology, Tel-Hashomer Hospital, Tel-Aviv, Israel
4
Center for Clinical and Translational Science, Rockefeller University,
New York, USA
5
Department of Dermatology, Icahn School of Medicine at Mount Sinai,
New York, USA
33
34
Accepted Abstracts
P065
The function of miR-146 family in the regulation of proliferation of
keratinocytes: implication in psoriasis
H. Hermann1, T. Runnel1, A. Aab1, L. Šahmatova2, J Maslovskaja1, B. Rückert3,
K. Kingo2, C. A. Akdis3, A. Rebane1
1Institute of Biomedicine and Translational Medicine, University of Tartu, Estonia
2Department of Dermatology and Venereology, University of Tartu, Estonia
3Swiss Institute of Allergy and Asthma Research, University of Zürich, Davos,
Switzerland
P066
HLA-class II-restricted activation of desmoglein 3-specific CD4+
T cells is required for the formation of pathogenic antibodies in a
mouse model of pemphigus vulgaris
R. Eming1, T. Hennerici1, J. Bäcklund2, C. Feliciani3, K. Visconti4, S. Willenborg1,
J. Wohde1, R. Holmdahl2, G. Sonderstrup4, M. Herti1
1Department of Dermatology and Allergology; Philipps-Universität Marburg,
Marburg, Germany
2Department of Medical Biochemistry and Biophysics, Karolinska Institutet,
Stockholm, Sweden
3Section of Dermatology, Università degli Studi di Parma, Parma, Italy
4
Department of Microbiology and Immunology, Stanford University, Stanford, USA
P067
New potential members of psoriatic transcriptional regulatory
network
A. Zolotarenko1, S. Bruskin1
1Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow,
Russia
P068
Epidermal Protease-activated receptor-2 (PAR2) overexpression
causes spontaneous atopic dermatitis-like skin disease:
Neuro-Epidermal Communication
T. Buhl1, A. Ikoma2, F. Cevikbas2, C. Kempkes2, M. Sulk2, T. Aklyama3, E. Cartens3,
P. Elias2, S. R. Coughlin4, M. Steinhoff5
1Dermatology, UMG, Göttingen, Germany
2Dermatology, UCSF, San Francisco, USA
3Center of Neuroscience, UCD, Davis, USA
4
Cardiovascular Research Institute, UCSF, San Francisco, USA
5
Charles Institute for Translational Dermatology, UCD, Dublin, Ireland
Accepted Abstracts
P069
Comparative transcriptome analysis in rosacea subtypes display
features of the same disease complex without conclusive
consecutive evolution
M. Steinhoff1, M. Sulk3, V. Schwab3, P. Nowak3, J. Buddenkotte3, F. Cevikbas2,
C. Kempkes2, J. Aubert4, J. J. Voegel4, T. Buhl5
1Charles Institute for Translational Dermatology, UCD, Dublin, Ireland
3Dermatology, UKM, Münster, Germany
4
Molecular Dermatology, Galderma R&D, Sophia Antipolis, France
5
Dermatology, UMG, Göttingen, Germany
P070
Molecular and morphological Characterization of the inflammatory
Infiltrate in Rosacea: new Insights into immune Pathophysiology
M. Sulk2, P. Nowak2, J. Buddenkotte2, F. Cevikbas1, C. Kempkes1, J. Aubert3,
J.J. Voegel3, M. Ste-inhoff4, T. Buhl5
2Dermatology, UKM, Münster, Germany
3Molecular Dermatology, Galderma R&D, Sophia Antipolis, France
4
Charles Institute for Translational Dermatology, UCD, Dublin, Ireland
5
Dermatology, UMG, Göttingen, Germany
P071
NSAIDs not only sensitize melanoma cells to TRAIL-induced
apoptosis, but also induce TRAIL expression by innate immune cells
M. Vazquez-Strauss1, G. Stingl1
1DIAID, Medical University of Vienna, Vienna, Austria.
P072
Molecular IgE sensitization profiles differ between patients with
severe and moderate atopic dermatitis
I. Mittermann1,4, G. Wikberg2, C. Johansson3, C. Lupinek4, L. Lundeberg2,
R. Crameri5, A. Scheynius3
1Christian Doppler Laboratory for the Development of Allergen Chips, Vienna,
Austria
2Dermatology and Venereology Unit, Karolinska University Hospital, Stockholm,
Sweden
3Translational Immunology Unit, Department of Medicine, Karolinska Institutet,
Stockholm, Sweden
4
Division of Immunopathology, Department of Pathophysiology and Allergy
Research, Vienna, Austria
5
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich,
Davos, Switzerland
35
36
Accepted Abstracts
P073
Treatment with secukinumab rapidly leads to positive proteomic
and transcriptional changes in psoriatic skin
F. Kolbinger1, G. Bruin1, M. A. Valentin1, T. R. Peters1, E. Khokhlovich1, X. Jiang1,
I. Koroleva1, D. Lee1, F. SinneF2,3, T. Pieber2,3, C. Dragatin2, M. Bodenlenz2, C. Loesche1
1Novartis Institutes for BioMedical Research, Basel, Switzerland
2HEALTH – Institute for Biomedicine and Health Sciences, JOANNEUM RESEARCH
Forschungsgesellschaft mbH, Graz, Austria
3Division of Endocrinology and Metabolism, Department of Internal Medicine,
Medical University of Graz, Graz, Austria
P074
Higher activation and cytokine production in circulating
CLA+T-cells, suggestive of higher systemic inflammation,
in AD vs. psoriasis
T. Czarnowicki1, A. Shemer2, J. Gonzales3, J. Krueger1, E. Guttman-Yassky4
1Laboratory for Investigative Dermatology, The Rockefeller University, New York,
USA
2The Chaim Sheba Medical Center, Tel-Aviv University, Tel-Hashomer, Tel-Aviv,
Israel
3The Translational Technology Core Laboratory (CCTS, The Rockefeller
University), New York, USA
4
The Dermatology department at the Icahn School of Medicine at Mount Sinai,
New York, USA
P075
Effects of Experimental Psoriasis-like Skin Inflammation in
Atherosclerosis-prone Mice
M. Madsen1, P. R. Hansen2, L. Svensson3, L. B. Nielsen1,4, K. Hartvigsen1,
A. E. Pedersen5, J. P. Christensen5, T. X. Pedersen1
1Dept. of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
2Dept. of Cardiology, Gentofte University Hospital, Gentofte, Denmark
3LEO Pharma, Ballerup, Denmark
4
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
5
Dept. of International health, Immunology, and Microbiology, University of Cph,
Copenhagen, Denmark
Accepted Abstracts
P076
Increased Epidermal Elafin Expression is associated with a Poor
Prognosis of Cutaneous Graft-versus-Host Disease
M.-C. Brüggen1, P. Petzelbauer2, H. Greinix3, E. Contassot4, D. Jankovic4, L. French4,
G. Socié5, W. Rabitsch3, Z. Kuzmina3, P. Kalhs3, R. Knobler6, G. Stingl1, G. Stary1,7
Diseases, Medical University of Vienna, Vienna, Austria
2Department of Dermatology, Skin & Endothelium Research Division, Medical
University of Vienna, Vienna, Austria
3Department of Internal Medicine I, Bone Marrow Transplantation Unit, Medical
4
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
5
Department of Hematology Transplantation, AP-HP Hospital Saint Louis, Paris,
France
6
Department of Dermatology, Division of General Dermatology, Medical
7
Harvard Medical School, Department of Microbiology and Immunobiology,
Division of Immunology, Boston MA, USA
P077
Molecular Analysis of Intravascular Large B-Cell Lymphoma
W. Bauer1, M. Aichelburg1, J. Griss1, H. Kittler2, C. Skrabs3, I. Simonitsch-Klupp4,
A. Schiefer4, U. Jäger3, B. Streubel4, G. Stingl1
1Department for Dermatology, Division of Immunology, Allergy and Infectious
Diseases, Vienna, Austria
2Department for Dermatology, Division of General Dermatology, Medical
University, Vienna, Austria
3Clinical Department for Hematology and Hemostaseology, Department of
Medicine I, Vienna, Austria
4
Department of Pathology, Medical University of Vienna, Vienna, Austria
P078
A mucosal vaccine against Chlamydia trachomatis generates two
synergistic waves of protective memory T cells
G. Stary1, A. Olive1, A. F. Radovic-Moreno2,3, D. Gondek1, D. Alvarez1, P. A. Basto2,3,
M. Perro1, R. Langer2,3, M. N. Starnbach1, U. H. von Andrian1
1Division of Immunology, Department of Microbiology and Immunobiology,
Harvard Medical School, Boston, USA
2Harvard-MIT Division of Health Sciences & Technology, Cambridge, USA
3Department of Chemical Engineering, Massachusetts Institute of Technology,
Cambridge, USA
37
38
Accepted Abstracts
P079
Epigenetic control of IL-23 expression in keratinocytes by TNF and
N-WASP
H Li1, C. Brakebusch1
1Department of Biomedical Sciences, University of Copenhagen, Ole Maaløes
Vej 5, Copenhagen, Denmark
P080
Human primary macrophage activation in vitro by wound exudate
collected from chronic ulcers
F. Kalthoff2, B. Wolff-Winiski2, B. Liehl2, C. Weishaeupl2, E. Foglar2, K. Jahn-Bassler1,
W. Bauer1, E. Kriehuber2, G. Stingl1
1Dept. of Dermatology, Division of Immunology, Allergy and Infectious Diseases,
Medical University of Vienna, Vienna, Austria
2ATI/Dermatology, Novartis Institutes for BioMedical Research, Vienna, Austria
P081
Higher frequencies but impaired suppressive capacity of regulatory
T-cells after PUVA in cutaneous T-cell lymphoma
P. Vieyra-Garcia1, G. Mayer1, H. Pressl1, E. Reginato1, N. Schweintzger1, I. Bambach1,
F. Legat1, A. Hofer1, A. Gruber-Wackernagel1, L. Cerroni1, R. Fink-Puches1, P. Wolf1
1Department of Dermatology and Venereology, Medical University of Graz,
Austria
P082
Epicutaneous application of recombinant Bet v 1 and Bet v 1
derivatives induces allergen-specific IgG and T cell responses
R. Campana1, K. Moritz2, A. Neubauer3, H. Huber3, R. Henning 3, K. Blatt4,
G. Hoermann5, T. M. Brodie6, A. Kaider7, P. Valent4, F. Sallusto6, S. Wöhrl2, R. Valenta1
1Division of Immunopathology, Department of Pathophysiology, Center of
Physiology and Patho-physiology, Vienna General Hospital (AKH), Medical
University of Vienna, Austria
2Division of Immunology, Allergy and Infectious Diseases, Department of
Dermatology, Vienna General Hospital (AKH), Medical University of Vienna,
Austria
3Biomay AG, Vienna, Austria
4
Division of Hematology and Hemostaseology, Department of Internal Medicine
I, Vienna General Hospital (AKH), Medical University of Vienna, Austria
5
Department of Laboratory Medicine, Vienna General Hospital (AKH), Medical
University of Vienna, Austria
6
Cellular Immunology Laboratory, Institute for Research in Biomedicine,
Bellinzona, Switzerland
7
Center for Medical Statistics, Informatics and Intelligent Systems, Section for
Clinical Biometrics, Medical University of Vienna, Austria
Accepted Abstracts
P083
RNA-Seq profiling increases the atopic dermatitis transcriptome
and identifies novel pro-inflammatory genes with potential
therapeutic implications
M. Suarez-Fariñas1, B. Ungar2,1, M. Rozenblit2,1, H. Mitsui1, H. Xu2, J. G. Krueger1,
E. Guttman-Yassky2,1
1The Laboratory for Investigative Dermatology, The Rockefeller University,
New York NY, USA
2Department of Dermatology and Laboratory for Inflammatory Skin Diseases,
Icahn School of Medicine at Mount Sinai, New York, NY
P084
Identification of Novel Immune and Barrier Genes in Atopic
Dermatitis by Laser Capture Micro-dissection
H. Esaki1,2, D. A. Ewald1,3,4, B. Ungar1,2, M. Rozenblit1,2, X. Zheng1, H. Xu1,
Y. D. Estrada1,2, X. Peng1,2, H. Mitsui1, T. Litman3, M. Suárez-Fariñas1, J. G. Krueger1,
E.Guttman-Yassky1,2
1The Laboratory for Investigative Dermatology, The Rockefeller University,
New York, USA
2Department of Dermatology and Laboratory for Inflammatory Skin Diseases,
Icahn School of Medicine at Mount Sinai, New York, USA
3Molecular Biomedicine, LEO Pharma, Ballerup, Denmark
4
Center for Microbial Biotechnology, DTU Systems Biology, Technical University
of Denmark, Lyngby, Denmark
P085
A retrospective single-center cohort analysis of 118 patients with
moderate to severe hidradenitis suppurativa
L. Oberleitner1, P. Viznerova1, E. Riedl1
1Department of Dermatology, Medical University of Vienna, Vienna, Austria
P086
Correlation of a novel histopathologic Psoriasis score with clinical
disease scores in plaque-type psoriasis
E. Riedl1, H. Kittler1, T. Kopp1, S. Khalilieh2
1Department of Dermatology, Medical University of Vienna, Vienna, Austria,
2Merck & Co., Inc., Whitehouse Station NJ, USA
P087
Personality traits impact the quality of life assessment in patients
with psoriasis
A. Wesinger1, P. Viznerova1, E. Lehner-Baumgartner2, H. Kittler1, H. Pehamberger1,
E. Riedl1
1Department of Dermatology, Division of General Dermatology, Medical University
of Vienna, Vienna, Austria
2Department of Clinical Psychology, Vienna General Hospital, Vienna, Austria
39
Accepted Abstracts
Prescribing Information see page 42
40
*Enbrel is indicated for moderate-to-severe plaque psoriasis.
References: 1. Nast A et al. JDDG. 2012;10(Suppl 2):S1-S95. 2. Menter A, Gottlieb A et al. J Am Acad Dermatol. 2008;58:826-850.
3. Watson T & de Bruin D. Indo-Pacific Journal of Phenomenology. 2006;6(2):1-12. 4. Gottlieb AB. Nature Rev Drug Discov. 2005;4(1):19-34.
EU-ENB41014. Date of preparation: October 2014.
ENB-130-14/1/10.10.2014.
Accepted Abstracts
Help your psoriasis patients follow their
unique and changing path in life*
41
42
Commercial Exhibition/Sponsorship
EXHIBITION HOURS
15:00 – 21:00
09:00 – 21:00
08:00 – 11:00
LIST OF EXHIBITORS
Bayer
Celgene
Eli Lilly
Galderma
Janssen
Medimmune
Merck
Novartis
Stiefel/GSK
Ins Enbrel 21.10.14 11:28 Seite 3
Prescribing Information page 40-41
Enbrel 25 mg powder and solvent for solution for injection, Enbrel 25 mg solution for injection in pre-filled syringe,
Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled pen, Enbrel 10
mg powder and solvent for solution for injection for paediatric use. Qualitative and quantitative composition: Each vial
contains 10/25 mg of etanercept, each pre-filled syringe contains 25 mg/ 50 mg of etanercept, each pre-filled pen contains 50
mg of etanercept. List of excipients: Enbrel 25 mg powder and solvent for solution for injection & Enbrel 10 mg powder and
solvent for solution for injection for paediatric use: Powder: Mannitol (E421), sucrose, trometamol. Solvent: Water for injections.
Enbrel 25 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 50 mg
solution for injection in pre-filled pen: Sucrose, sodium chloride, L-Arginine hydrochloride, sodium phosphate monobasic
dehydrate, sodium phosphate dibasic dehydrate, water for injections. Therapeutic indications: Enbrel 25 mg powder and
solvent for solution for injection, Enbrel 25 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in
pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled pen: Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic
arthritis, axial spondyloarthritis: Ankylosing spondylitis (AS) & non-radiographic axial Spondyloarthritis, plaque psoriasis,
paediatric plaque psoriasis. Enbrel 10 mg powder and solvent for solution for injection for paediatric use: Juvenile idiopathic
arthritis, paediatric plaque psoriasis. (For details please refer to the Summary of Product Characteristics). Contraindications:
Hypersensitivity to the active substance or to any of the excipients. Sepsis or risk of sepsis. Treatment with Enbrel should not
be initiated in patients with active infections, including chronic or localised infections. Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF- ) inhibitors, ATC code: L04AB01. Marketing authorization holder: Pfizer
Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom. Date of revision of the text: 07/2014. General
classification for supply: Subject to medical prescription, available in pharmacies only, non-renewable prescription. For details
of special warnings and precautions for use, interaction with other medicinal products and other forms of interaction,
pregnancy and lactation and undesirable effects please refer to the published Summary of Product Characteristics.
Platinum Sponsors
Gold Sponsors
Silver Sponsors
Regular Sponsors
43
44
Industry-Supported Sessions
12:00 – 14:00
Regeneron and Sanofi Satellite Symposium
Atopic Dermatitis: New Understandings of Pathology,
New Advances in Therapy
12:00 – 12:30 Registration and Lunch
12:30 – 12:40 Chairman’s Introductory Remarks
12:40 – 13:00 Assessing the Current Treatment Landscape in Atopic Dermatitis:
Our Patients’ Needs Are Not Being Met
Georg Stingl (Vienna, AT)
13:00 – 13:20 Loss of Function Mutations in the FLG Gene, Skin Barrier
Dysfunction and Allergic Sensitization
Matthias Schmuth (Innsbruck, AT)
13:20 – 13:40 From Bench to Bedside: Translating New Understandings of
Pathology Into Therapy
13:40 – 14:00 Question and Answer Session
15:30 – 17:00
Pfizer Satellite Symposium
15.30 – 15.35 Welcome and introduction
Robert Strohal (Feldkirch, AT)
15.35 – 16:05 The need for a patient-centered approach in psoriasis
Robert Strohal (Feldkirch, AT)
16:05 – 16:35 Maintaining long-term response in psoriasis:
Role of immunogenicity
Manuel Carrascosa (Barcelona, ES)
16:35 – 17:00 Using our wealth of experience to shape the future of patient-care
Frank Nestle (London, UK)
Ins. Xolair 21.10.14 11:22 Seite 2
Prescribing Information page 4
BEZEICHNUNG DES ARZNEIMITTELS: Xolair 75 mg Injektionslösung – Xolair 150 mg Injektionslösung – Omalizumab
QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG: Xolair 75mg Injektionslösung: Jede Fertigspritze mit 0,5 ml
Lösung enthält 75 mg Omalizumab*. Xolair 150 mg Injektionslösung: Jede Fertigspritze mit 1 ml Lösung enthält 150 mg
Omalizumab. *Omalizumab ist ein humanisierter monoklonaler Antikörper, der durch rekombinante DNA-Technologie in einer
Säugetier-Zelllinie aus dem Ovar des chinesischen Hamsters (CHO) hergestellt wird. Vollständige Auflistung der sonstigen
Bestandteile, siehe Abschnitt 6.1. der Fachinformation. Liste der sonstigen Bestandteile: L-Argininhydrochlorid, L-Histidinhydrochlorid, L-Histidin, Polysorbat 20, Wasser für Injektionszwecke. Anwendungsgebiete: Xolair 75 mg Injektionslösung:
Xolair wird angewendet bei Erwachsenen, Jugendlichen und Kindern (6 bis <12 Jahre). Die Behandlung mit Xolair sollte nur bei
Patienten in Betracht gezogen werden, bei denen von einem IgE-(Immunglobulin E-)vermittelten Asthma ausgegangen werden
kann (siehe Abschnitt 4.2 der Fachinformation). Erwachsene und Jugendliche (ab 12 Jahren): Xolair wird als Zusatztherapie zur
verbesserten Asthmakontrolle bei Patienten mit schwerem persistierendem allergischem Asthma angewendet, die einen
positiven Hauttest oder In-vitro-Reaktivität gegen ein ganzjährig auftretendes Aeroallergen zeigen und sowohl eine reduzierte
Lungenfunktion (FEV1 <80 %) haben als auch unter häufigen Symptomen während des Tages oder nächtlichem Erwachen
leiden und trotz täglicher Therapie mit hoch dosierten inhalativen Kortikosteroiden und einem lang wirkenden inhalativen Beta2Agonisten mehrfach dokumentierte, schwere Asthma-Exazerbationen hatten. Kinder (6 bis <12 Jahre): Xolair wird als Zusatztherapie zur verbesserten Asthmakontrolle bei Patienten mit schwerem persistierendem allergischem Asthma angewendet, die
einen positiven Hauttest oder in vitro Reaktivität gegen ein ganzjährig auftretendes Aeroallergen zeigen und unter häufigen
Symptomen während des Tages oder nächtlichem Erwachen leiden und trotz täglicher Therapie mit hoch dosierten inhalativen
Kortikosteroiden und einem lang wirkenden inhalativen Beta2-Agonisten mehrfach dokumentierte, schwere AsthmaExazerbationen hatten. Xolair 150 mg Injektionslösung: Allergisches Asthma: Xolair wird angewendet bei Erwachsenen,
Jugendlichen und Kindern (6 bis <12 Jahre). Die Behandlung mit Xolair sollte nur bei Patienten in Betracht gezogen werden,
bei denen von einem IgE-(Immunglobulin E-)vermittelten Asthma ausgegangen werden kann (siehe Abschnitt 4.2). Erwachsene
und Jugendliche (ab 12 Jahren): Xolair wird als Zusatztherapie zur verbesserten Asthmakontrolle bei Patienten mit schwerem
persistierendem allergischem Asthma angewendet, die einen positiven Hauttest oder In-vitro-Reaktivität gegen ein ganzjährig
auftretendes Aeroallergen zeigen und sowohl eine reduzierte Lungenfunktion (FEV1 <80 %) haben als auch unter häufigen
Symptomen während des Tages oder nächtlichem Erwachen leiden und trotz täglicher Therapie mit hoch dosierten inhalativen
Kortikosteroiden und einem lang wirkenden inhalativen Beta2-Agonisten mehrfach dokumentierte, schwere AsthmaExazerbationen hatten. Kinder (6 bis <12 Jahre): Xolair wird als Zusatztherapie zur verbesserten Asthmakontrolle bei Patienten
mit schwerem persistierendem allergischem Asthma angewendet, die einen positiven Hauttest oder in vitro Reaktivität gegen
ein ganzjährig auftretendes Aeroallergen zeigen und unter häufigen Symptomen während des Tages oder nächtlichem Erwachen
leiden und trotz täglicher Therapie mit hoch dosierten inhalativen Kortikosteroiden und einem lang wirkenden inhalativen Beta2Agonisten mehrfach dokumentierte, schwere Asthma-Exazerbationen hatten. Chronische spontane Urtikaria (csU): Xolair wird
als Zusatztherapie für die Behandlung der chronischen spontanen Urtikaria bei Erwachsenen und Jugendlichen (ab 12 Jahren)
mit unzureichendem Ansprechen auf eine Behandlung mit H1-Antihistaminika angewendet. Gegenanzeigen: Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile. Pharmakotherapeutische Gruppe: Mittel bei obstruktiven
Atemwegserkrankungen, andere Mittel bei obstruktiven Atemwegserkrankungen zur systemischen Anwendung, ATC-Code:
R03DX05. INHABER DER ZULASSUNG: Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex, RH12 5AB,
Vereinigtes Königreich. Verschreibungspflicht/Apothekenpflicht: NR, apothekenpflichtig. Informationen betreffend Warnhinweise und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkung mit anderen Mitteln, Nebenwirkungen und Gewöhnungseffekte sind den veröffentlichten Fachinformationen zu entnehmen. Version: 02/2014
45
46